Status of Share Repurchase in Accordance with the Board Resolution as of August 7, 2024
(Share repurchase under the provisions of SBG’s Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act of Japan)
SoftBank Group Corp. (“SBG”) today announced the status of the repurchase of its own shares conducted in September 2024 as follows, pursuant to Article 156 of the Companies Act of Japan as applied pursuant to Article 165, Paragraph 3.
| (1) Class of shares repurchased: | Common stock of SBG |
|---|---|
| (2) Total number of shares repurchased: | 3,314,700 |
| (3) Total amount of repurchase: | JPY 26,913,472,300 |
| (4) Repurchase period: | From September 2, 2024 to September 20, 2024 (execution base) |
For Reference:
1. Details of the resolution made by the Board of Directors on August 7, 2024
| (1) Class of shares to be repurchased: | Common stock of SBG |
|---|---|
| (2) Total number of repurchasable shares: | 100,000,000 (maximum) |
| (3) Total amount of repurchase: | JPY 500 billion (maximum) |
| (4) Repurchase period: | From August 8, 2024 to August 7, 2025 |
2. Cumulative number of shares repurchased based on the resolution made by the Board of Directors on August 7, 2024 (as of September 30, 2024)
| (1) Total number of shares repurchased: | 19,117,700 |
|---|---|
| (2) Total amount of repurchase: | JPY 153,785,475,200 |
-
Releases, announcements, presentations and other information available from this page and elsewhere on this website were prepared based on information available and views held at the time of preparation and speak only as of the respective dates on which they are filed or used by SoftBank Group Corp. or the applicable group company, as the case may be. Such information is subject to change and may become out-of-date. Such information may also contain forward-looking statements which are by their nature subject to various risks and uncertainties that may cause actual results and future developments to differ materially from those expressed or implied by such statements. Please read legal notices in its entirety prior to viewing any information available on this website.
